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http://dx.doi.org/10The transcription factor GATA2 is highly expressed in hematopoietic stem cells and is down-
regulated during lineage maturation. Gain of function mutations, loss of function mutations,
and overexpression of GATA2 have been reported in acute myeloid leukemia. In previous
studies, we and others showed that GATA2 overexpression at high levels, similar to that
seen in hematopoietic stem cells, blocked differentiation of hematopoietic stem cells and pro-
genitors. To better understand the effects of GATA2, we designed a Tamoxifen-inducible
GATA2-estrogen receptor (ERT) vector. In the absence of Tamoxifen, small amounts of
GATA2-ERT were still able to enter the nucleus in mouse bone marrow (BM) cells, providing
us with a tool to test the effects of low-level GATA2 overexpression. We observed that this low-
level GATA2 overexpression enhanced self-renewal of myeloid progenitors in vitro and re-
sulted in immortalization of BM cells to myeloid cell lines. Continuous GATA2-ERT expres-
sion was required for the proliferation of these immortalized lines. Myeloid expansion and
a block in T and B lineage differentiation were observed in mice transplanted with GATA2-
ERT-expressing BM cells. Myeloid expansion occurred after the granulocyte monocyte
progenitor stage, and lymphoid block was distal to the common lymphoid progenitor in
transgenic mice. GATA2 appeared to induce growth via downstream activation of Nmyc
and Hoxa9. Our results demonstrate that GATA2 overexpression at low level confers
self-renewal capacity to myeloid progenitors and is relevant to myeloid leukemia
development. Copyright  2015 ISEH - International Society for Experimental Hematology.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The zinc-finger transcription factor GATA2 is critically
required for developmental specification of hematopoietic
stem cells (HSCs) and has been implicated in leukemic
transformation. In mouse chimeras, Gata2/ cells failed
to contribute to the adult hematopoietic system, indicating
that GATA2 is cell-autonomously required during hemato-
poietic development [1]. Subsequent studies have revealed
that GATA2 is required for the endothelial to hematopoietico: Dr. Satish K. Nandakumar, St. Jude Children’s
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.1016/j.exphem.2015.04.002transition of HSCs as they are born from the dorsal aorta in
the aorta gonads mesonephros [2].
The role of GATA2 in adult hematopoiesis is less clear, but
GATA2 is highly expressed in bone marrow (BM) HSCs and
downregulated during lineage commitment [3–6], suggesting
an important role in early progenitors as well as the idea that
prolonged high expression is undesirable. Consistent with
this possibility,GATA2 is overexpressed in the BMof both pe-
diatric and adult acute myeloid leukemia patients, and aber-
rant GATA2 expression is also observable in leukemic blasts
[7–10]. Patients in remission display GATA2 levels that return
to normal, whereas patients with resistant disease display
continued GATA2 overexpression [8]. Gain of function muta-
tions in GATA2 have been reported during blast crisis in
chronic myeloid leukemia [11]. Taken together, these results
suggest that elevated GATA2 activity, although normal inatology. Published by Elsevier Inc. This is an open access article under the
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to unwanted proliferation and myeloid malignancy.
To test the effects ofGATA2 overexpression, we and others
previously took a retroviral-mediated approach [12,13]. Sur-
prisingly, the high-level GATA2 overexpression achieved by
this means in murine and human HSCs resulted in loss of
HSC reconstitution potential and loss of colony-forming
potential in vitro due to cellular quiescence [12,13], suggest-
ing that GATA2 actually opposes proliferation.
Interestingly,GATA2activity elevation in leukemic blasts is
lower than the high levels observed endogenously in BM
CD34þ cells [10], raising the possibility that elevated low-
level and high-level expressionmight have different cellular ef-
fects. In an attempt to better understand the effects of GATA2
on lineage maturation, we developed a Tamoxifen (TAM)-
inducible GATA2-estrogen receptor (ERT) construct that
would provide us with a means to regulate activity. This
construct displayed constitutive low-level nuclear localization,
even in the absence of TAM (‘‘leakiness’’), providing us with
the means to examine the effects of low-level overexpression.
Themost important feature of the leaky overexpression is that it
more closely replicates the elevated levels observed physiolog-
ically in leukemia, whereas prior gain-of-function studies
examined overexpression levels dramatically higher than those
observed in leukemia [12,13].Our study is thus an investigation
of the consequences of low-levelGATA2 overexpression that is
much more representative of the elevated levels observed in
disease. Our findings indicate that low-level GATA2 overex-
pression supports many of the behaviors required for leukemo-
genesis, but indicate that additional cooperating mutations are
likely required for frank transformation.
Methods
Retroviral vector design and production
The gamma-retroviral constructs, murine stem cell virus (MSCV)-
GATA2–internal ribosome entry site (IRES)–green fluorescent
protein (GFP) hereinafter referred to as ‘‘GATA2 vector’’ and
MSCV-IRES-GFP (‘‘GFP vector’’) were described previously
[12]. To generate MSCV-GATA2-ERT-IRES-GFP (‘‘GATA2-
ERT vector’’) vector, human GATA2 cDNA was cloned 50 to the
G521R variant of the estrogen receptor ligand-binding domain
(ERT) [14]. Our cloning strategy removed the stop codon and
the last amino acid from GATA2 cDNA and generated a seven-
amino-acid linker (NSDPRNE) between GATA2 and ERT.
C352P and C370P GATA2 mutants were generated using
Phusion Site-Directed Mutagenesis kit (Thermo Scientific, Wal-
tham, MA) in a pUC19 GATA2 vector. The mutant zinc finger do-
mains were then shuttled into the retroviral GATA2-ERT vector,
using SacII and BamHI sites to generate the MSCV-GATA2C352P-
ERT-IRES-GFP (‘‘C352P’’) and MSCV-GATA2C370P-ERT-IRES-
GFP (‘‘C370P’’) vectors. Polyclonal populations of ecotrophic
retroviral packaging cells (GPE-86 cells) were generated, and vec-
tor supernatants were collected as previously described [12].
Colony-forming assay and cell culture
Bone marrow cells were isolated from 8–12-week-old C57Bl/6
mice. Lineage-positive cells were depleted by Lineage Cell Deple-tion Kit and the autoMACS separation system (Miltenyi Biotec, San
Diego, CA). After 48 hours of prestimulation, cells were transduced
four times every 12 hours with retroviral supernatants (Multiplicity
of Infection 1–3) on Retronection coated plates (Takara, Madison,
WI) with polybrene (6 mg/mL). Forty-eight hours posttransduction,
cells were plated for colony-forming units in culture (CFU-C) assay
in M3434 media (Stem Cell Technologies, Vancouver, Canada) or
grown in suspension culture. Colonies were counted every 7 days
and replated at the appropriate cell numbers. Bone marrow cells
were cultured with mouse interleukin (IL) 3 (20 ng/mL), human
IL-6 (50 ng/mL), and mouse stem cell factor (50 ng/mL; Peprotech,
Rocky Hill, NJ) in Dulbecco’s modified Eagle’s medium with 15%
fetal bovine serum (Hyclone, Logan, UT).
Protein extraction and immunoblot
Total protein was extracted by boiling cells for 5 min in Laemelli
buffer (Bio-Rad, Waltham, MA) containing beta-mercaptoethanol,
protease inhibitor cocktail (Sigma-Aldrich, Haverhill, MA), and 4-
(2-Aminoethyl)-benzenesulfonylfluoride hydrochloride (Gold
Biotechnology, St. Louis, MO). Subcellular fractionation was per-
formed using Qproteome cell compartment kit (QIAGEN, Valencia,
CA). Antibodies used in the immunoblot are detailed in
Supplementary Table E1 (online only, available at www.exphem.org).
Knockdown experiments on GATA2-ERT cells
GATA2-ERT cells were transduced three times every 24 hours
with lentiviral small hairpin RNA (shRNA) vector supernatants
(MOI 15–20) on Retronection-coated plates. Forty-eight hours
posttransduction, cells were lifted and plated at 3  105 cells/
mL and split every 3 days. Flow cytometry for m-cherry% and
Gr-1% was performed at the time points indicated.
Competitive transplantation
Bone marrow was harvested from 8–12-week-old C57Bl/6
mice (The Jackson Laboratory, Bar Harbor, ME) 48 hours post-
treatment with 150 mg/kg 5-fluorouracil (Pharmacia, Stockholm,
Sweden). After 24 hours prestimulation, retroviral transduction
was performed as described above. The transduced cells were
either diluted with untransduced cells or kept undiluted and in-
jected by tail vein (2.5  106 cells) into C57Bl/6 recipients irradi-
ated at 1,125 cGy. Peripheral blood analysis on the recipients was
performed at 8, 12, 16, and 20 weeks posttransplant. All experi-
ments were performed under protocols approved by the Institu-
tional Animal Care and Use Committee at St Jude Children’s
Research Hospital (Memphis, TN).
GATA2-ERT transgenic mice
The GATA2-ERT transgenic mice were generated by transduction
of murine blastocysts with lentiviral pCL10.1 MSCV-GATA2-
ERT-IRES-GFP vector supernatants, as previously described
[15]. The GATA2-ERT transgenic mice were routinely identified
by high GFP marking in Gr1þMac1þ cells in peripheral blood.
Affymetrix array hybridization
For microarray on LinSca1þKitþ (LSK) cells, approximately
20 ng total RNA was processed using NuGEN (San Carlos, CA)
WTA pico v2 and Encore Biotin labeling modules, and 6 mg of
biotin-labeled cDNA was hybridized overnight to HT_MG-
430_PM microarray chips (Affymetrix, Santa Clara, CA). Hybrid-
ized arrays were scanned using the Gene Titan (Affymetrix, Santa
Clara, CA) system, and signals were summarized using the Robust
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v6.5, Partek, St. Louis, MO). Differential expression between
GATA2-ERT expressing and nonexpressing LSKs was determined
from three independent experiments using the local pooled error t
test with an false discovery rate (FDR) ! 0.05 [16]. Gene set
enrichment analysis was performed as previously described [17].
For microarray on GATA2-ERT and control cell lines, 1 mg of
total RNAwas processed using eukaryote one-cycle target labeling
protocol, and biotin-labeled cRNA was hybridized overnight to
430v2 GeneChip (Affymetrix, Santa Clara, CA). Probesets with
greater than twofold difference in each of the three independent
GATA2-ERT cell lines versus the control GFP cell line and with
at least one present call were selected. Gene ontology and pathway
analysis was performed using the Database for Annotation, Visu-
alization and Integrated Discovery (DAVID, http://david.abcc.
ncifcrf.gov).
Electrophoretic mobility shift assay
Wild-type and mutant GATA2 and GATA2-ERT proteins were
synthesized from pCDNA3.1 expression plasmids using the
Rabbit reticulocyte TnT kit (Promega, Madison, WI). P32-labeled,
double-stranded oligonucleotide containing the a-globin promoter
(50-GATCTCCGGCAACTGATAAGGATTCCCTG-30) was incu-
bated with the protein lysates in the presence or absence ofFigure 1. GATA2-ERT displays functional in vitro activity in the absence of TAM
vectors were plated in semisolid media (Methocult M3434) in the presence of 10
colonies were counted to calculate the percentage of GFPþ CFU-C (n 5 3). (B) R
Cs from GFP-, GATA2-ERT-, and mock-transduced BM cells were tested for seria
replated every 7 days after plating. Cells were plated at 5  103 per plate in the p
plating, respectively.500 molar excess of unlabeled, double-stranded oligonucleotides.
Binding reactions contained 10 mmol/L Tris, pH 8.0, 40 mmol/L
KCl, 0.05% NP-40, 6% glycerol, 1 mmol/L Dithiothreitol, 0.2 g
poly dI/dC, 200 mmol/L ZnCl2, and 5 mL of synthesized GATA2
and GATA2-ERT lysates. Samples were incubated at 4C over-
night, resolved through a nondenaturing 4% polyacrylamide gel,
and analyzed using the Storm 860 phosphoimager (Molecular
Dynamics, Sunnyvale, CA).Results
Tamoxifen-independent GATA2-ERT function promotes
self-renewal in colony-forming assays
We previously demonstrated that BM progenitors and stem
cells subjected to enforced expression of GATA2 from a
retroviral vector show complete loss of colony-forming
activity in vitro and a loss of repopulating ability in vivo
[12]. We developed a GATA2-ERT vector designed
to retain GATA2 in the cytosol until administration of
TAM allows translocation to the nucleus (Supplementary
Figure E1A, online only, available at www.exphem.org).
Our GATA2-ERT vector was first tested for TAM-induced. (A) Bone marrow cells transduced with GFP, GATA2, and GATA2-ERT
0 nmol/L Tamoxifen or ethanol. Seven days later, total and GFPþ primary
epresentative images of primary colonies in the absence of TAM. (C) CFU-
l replating competence (n 5 3). Total colonies were scored, harvested, and
rimary plating, followed by 2.5  104 per plate for secondary and tertiary
568 S.K. Nandakumar et al./ Experimental Hematology 2015;43:565–577reduction in colony-forming activity. Consistent with previ-
ous results, the proportion of GFPþ colonies formed using
the GATA2 vector was eightfold lower than the control
GFP vector, irrespective of TAM treatment (Fig. 1A). In
contrast, the GATA2-ERT–vector-transduced BM cells in
the absence of TAM formed colonies similar in proportion
to the control GFP-vector-transduced cells. However, in the
presence of 100 nmol/L TAM, there was a thirteenfold
reduction in the GATA2-ERT colonies, an effect similar
to that observed in the GATA2 vector. These results indicate
that GATA2-ERT vector, in the presence of TAM, is able to
reproduce the effects of GATA2 overexpression.
Surprisingly, the sizes of GATA2-ERT colonies in the
absence of TAM were consistently larger than mock and
control GFP vector colonies (Fig. 1B). To determine whether
larger colony size was associated with increased self-renewal
capacity, we tested the GATA2-ERT vector against the con-
trol vector in a serial colony-replating assay. Cells harvested
from primary colonies of GATA2-ERT–transduced cells
were able to consistently generate fourfold higher secondary
colonies than GFP-transduced cells (Fig. 1C). When replatedFigure 2. GATA2-ERT immortalizes primary BM cells as myeloid cell lines. (A)
and GFP vectors compared with untransduced cells. Cells were counted at th
mean 6 SD for three independent experiments. (B) Wright-Giemsa-stained cyto
markers (c-kit, FcεRI) and myeloid markers (Gr-1, Mac-1). (D) Subcellular loca
with 100 nmol/L TAM or ethanol for 3 hours, compared with untreated cells. Pr
and nuclear and Western blotted for GATA2-ERT, glyceraldehyde 3-phosphate de
using an anti-ER antibody. Cyto 5 Cytoplasmic; EtOH 5 ethanol; GAPDH 5 gly
ERT.for tertiary colonies, only the GATA2-ERT–transduced cells
retained cells with colony-forming, clonogenic potential.
Our results are consistent with the possibility that GATA2-
ERT vector instructs self-renewal and/or proliferative
behavior in the absence of TAM.
Tamoxifen-independent GATA2-ERT function promotes
growth in liquid culture
Given the effects of GATA-2ERT expression on serial
replating potential in hematopoietic progenitors, we next
tested whether expression might have effects on cells
propagated in liquid cultures. Transduced BM cells were
cultured in Dulbecco’s modified Eagle’s medium with
15% fetal bovine serum in the presence of IL-3, IL-6,
and stem cell factor. Under these conditions, normal,
untransduced BM cells cease to proliferate at 3–4 weeks,
becoming mast cells [18]. GATA2-ERT–transduced BM
cells showed greater proliferation compared with the
GFP-transduced and untransduced cells (Fig. 2A),
frequently resulting in establishment of immortalized
cell lines (six out of seven experiments). Wright-GiemsaGrowth curves of lineage-depleted BM cells transduced with GATA2-ERT
e time points indicated by trypan blue exclusion. Results are shown as
spin slides at day 27. (C) FACS analysis at day 28 staining for mast-cell
lization of GATA2-ERT protein in GATA2-ERT cell lines after treatment
oteins from GATA2-ERT cell lines were subfractionated into cytoplasmic
hydrogenase (cyto), and Lamin B (Nuc). GATA2-ERT protein was detected
ceraldehyde 3-phosphate dehydrogenase; nuc 5 nuclear; WCL5 GATA2-
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were composed of immature myeloid cells with some
spontaneous differentiation (Fig. 2B). This result was
confirmed by fluorescence-activated cell sorting (FACS)
analysis, which showed that GATA2-ERT cells express
markers of myeloid progenitors (cKit, 62%; Mac1, 90%;
Gr1, 37%) compared with controls, which express mast
cells markers (cKit, 100%; FcER1, 100%; Fig. 2C). The
control GFP vector immortalized BM cells in only one
case (one out of seven experiments), resulting in a GFP
cell line. All immortalized cell lines were IL-3 dependent.
Upon treatment with 100 nmol/L of TAM, all GATA2-
ERT cell lines stopped proliferating (Supplementary
Figure E2A, online only, available at www.exphem.org),
similar to behavior in CFU-C assays. Cells were arrested
in the G0/G1 phase as early as 24 hours post-TAM-
treatment in GATA2-ERT cell lines (Supplementary
Figure E2B, online only, available at www.exphem.org).
Thus, GATA2-ERT causes growth arrest in the presence
of TAM, yet causes IL-3–dependent immortalization in
the absence of TAM.
GATA2-ERT displays Tamoxifen-independent nuclear
localization
Increased proliferation and colony formation caused by
GATA2-ERT vector in the absence of TAM might result
from low-level GATA2-ERT entry into nucleus, which has
been reported in other inducible vectors like mycER and
creER [19,20]. To examine the possibility that GATA2-
ERT translocates to the nucleus in the absence of TAM,
we performed subcellular fractionation of untreated,
TAM-treated (100 nmol/L), and ethanol (vehicle)-treated
GATA2-ERT cell lines. As expected, TAM treatment
resulted in complete nuclear GATA2-ERT protein localiza-
tion (Fig. 2D). Interestingly, GATA2-ERT protein was
detected in both the nuclear and cytoplasmic fractions of
untreated and vehicle-treated cells (Fig. 2D). The level of
nuclear GATA2-ERT in the absence of TAM would be
expected to result in low-level tonic activity, at least
twofold lower than with the complete translocation caused
by TAM. We immunostained untreated and TAM-treated
GATA2-ERT cell lines (Supplementary Figure E3A, online
only, available at www.exphem.org) and retroviral pack-
aging cells (Supplementary Figure E3B, online only, avail-
able at www.exphem.org) and visualized the results by
confocal imaging. In the absence of TAM, both populations
exhibited nuclear GATA2-ERT colocalized with 4,6-
diamino-2-phenylindole (DAPI). Upon TAM administra-
tion, the intensity of nuclear GATA2-ERT increased,
demonstrating enhanced nuclear translocation, and little
or no cytoplasmic GATA2-ERTwas observed in these cells.
These data confirm low but significant nuclear levels of
GATA2-ERT in the absence of TAM. We also measured
both endogenous GATA2 and GATA2-ERT levels by using
a polyclonal GATA2 antibody in Lin BM cells posttrans-duction. Transduction of GATA2-ERT vector resulted in a
twofold increase in endogenous GATA2 levels
(Supplementary Figure E4, online only, available at www.
exphem.org). Owing to the instability of the endogenous
GATA2 protein, we could not measure its nuclear levels.
Myeloid immortalization is dependent on GATA2-ERT,
HoxA9, and Nmyc
To determine whether GATA2-ERT-immortalized cell lines
are dependent on low-level tonic GATA2 activity for prolif-
eration, we examined the effects of GATA2-ERT knock-
down, using shRNA-containing lentiviral vectors carrying
a mCherry reporter (Supplementary Figure E5A, online
only, available at www.exphem.org). We used four vectors
targeting human GATA2 sequence (shGATA2) and one vec-
tor targeting the GFP sequence (shGFP) with GATA2-ERT
protein knockdown ranging from 50%–90% compared with
nonsilencing (NS) vector (Supplementary Figure E5B,
online only, available at www.exphem.org). The shGATA2-
and shGFP-transduced cells grew more slowly than untrans-
duced cells in liquid culture, as shown by a progressive reduc-
tion in mCherry% over an 18-day period, compared with the
NS-transduced cells, which had a stable mCherry%
(Fig. 3A). Three independent immortalized GATA2-ERT
cell lines consistently showed growth impairment with shGFP
vector, whereas a randomly immortalized GFP cell line
showed no growth defect (Supplementary Figure E5C, online
only, available at www.exphem.org). To identify the nature of
the growth defect associated with GATA2-ERT knockdown,
we examined cell cycle, cell death, and differentiation of
GATA2-ERT cell lines after transduction with shGFP vector.
No increase in dead cells was observed in these cultures,
based on trypan blue staining. However, cell cycle analysis us-
ing Hoechst staining revealed a decrease in cycling cells after
GATA2-ERT knockdown (Supplementary Figure E5D, online
only, available at www.exphem.org), which also correlated
with an increase in Gr1þ differentiated cells in these cultures
(Supplementary Figure E5E, online only, available at www.
exphem.org). Taken together, these data demonstrate that
expression of GATA2-ERT remains essential for self-
renewal and proliferation of the myeloid progenitors after
immortalization, and loss of GATA2-ERT leads to their rapid
differentiation into noncycling, Gr1þ, mature cells.
We wanted to determine what factors might mediate
the increased proliferative behavior instructed by low-
level nuclear GATA2-ERT. We therefore performed gene
expression analysis to identify genes differentially regu-
lated between three independent GATA2-ERT and control
cell lines (Tables 1 and 2). We observed differential
expression in 1,861 probesets between the GATA2-ERT
cell lines and the control cell line. Differentially regulated
genes were then grouped into genes regulating prolifera-
tion and hematopoiesis using the DAVID database. We
selected Nmyc and HoxA9 based on their effects on
myeloid progenitors in previous studies [21–23]. Real-
Figure 3. HoxA9 and Nmyc knockdown partially recapitulates GATA2-ERT loss in immortalized cell lines. (A) FACS analysis of m-cherry percentages of
GATA2-ERT cell lines transduced with the respective shRNA vectors targeting GATA2 at different time points in liquid culture. (B) Quantitative real-time
PCR analysis of gene expression of Nmyc, HoxA9, endogenous (m) and total (m þ h) GATA2 in GATA2-ERT cell lines (n 5 3) and a GFP cell line (n 5 1).
Gene expression is first normalized to Gapdh and represented as a ratio between GATA2-ERT and GFP cell lines. (C, D) FACS analysis of m-cherry per-
centages of GATA2-ERT cell lines transduced with the respective shRNA vectors targeting Nmyc and HoxA9 at different time points in liquid culture. (Color
version of this figure is available online.)
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regulation in Nmyc and HoxA9 of 50 and 2,400,
respectively, in the GATA2-ERT cell lines (Fig. 3B).
To determine whether these factors are required for
GATA2-ERT instruction of proliferative behavior, we
knocked them down in GATA2-ERT cells. ShRNA knock-
down of Nmyc and HoxA9 reduced mRNA expression by
30%–60% (Supplementary Figures E6A and E6B, online
only, available at www.exphem.org). GATA2-ERT cell
lines were transduced with knockdown vectors at similar
MOIs and grown in liquid culture for 3 weeks. As
expected, GATA2-ERT cells transduced with shGFP vec-
tor showed a significant growth disadvantage compared
with the NS vector in liquid culture. Nmyc and HoxA9
knockdown consistently resulted in a progressive decrease
in mCherryþ cells, but at a slower rate than for the shGFP
group (Fig. 3C and 3D). Knockdown of another top
differentially regulated gene, Bcl11a, did not have any
observed effect on the proliferation of the GATA2-ERT
cells (Supplementary Figures E7A and E7B, online
only, available at www.exphem.org). Our results are
consistent with the possibility that Nmyc and HoxA9 are
downstream mediators of GATA2-ERT proliferation
effects.Lymphoid block and myeloid expansion in recipients of
GATA2-ERT–transduced cells
To test the effects of low nuclear expression of GATA2
in vivo, we performed BM transplantation studies. Bone
marrow cells isolated from 5-fluorouracil-treated mice
were transduced with the GATA2-ERT and control GFP
vector at similar MOIs. Transduced cells were transplanted
into lethally irradiated recipients in the presence or absence
of a fourfold excess of competing mock-transduced cells.
At 12 weeks posttransplant, GFP expression in the periph-
eral blood of recipients was analyzed by flow cytometry.
Recipients of cells transduced with undiluted control GFP
vector showed similar GFP marking in B220þ cells
(58% 6 20), Thy1.2þ cells (58% 6 15), and Gr1þ myeloid
cells (84% 6 17; Fig. 4). In contrast, animals transplanted
with cells transduced with undiluted GATA2-ERT vector
showed very low GFP positivity in B220þ cells (8% 6 3)
and Thy1.2þ cells (14% 6 1), but high frequency in
Gr1þ cells (91% 6 3). These data indicate that GATA2-
ERT causes myeloid differentiation bias. Recipients of the
diluted GFP-vector-transduced cells showed the expected
lower percentages of GFP marking in all lineages compared
with the undiluted group (B cells, 6% 6 3; T cells,
15% 6 4; myeloid, 28% 6 18). However, the diluted
Table 2. Genes differentially expressed in GATA2-estrogen receptor
(ERT) vs. GFP cell line (hematopoiesis)
Hoxa9 homeo box A9 77.0
Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein) 36.8
Cd28 CD28 antigen 17.5
Eomes eomesodermin homologue (Xenopus laevis) 11.3
Hdac9 histone deacetylase 9 11.1
Clcf1 cardiotrophin-like cytokine factor 1 8.4
Ercc1 Excision repair cross-complementing rodent
repair deficiency, complementation group 1
7.6
Satb1 special AT-rich sequence binding protein 1 7.3
Pbx1 pre B-cell leukemia transcription factor 1 7.3
Tgfbr2 transforming growth factor, beta receptor II 5.8
Themis thymocyte selection associated 6.8
Card11 caspase recruitment domain family, member 11 7.8
Jag2 jagged 2 7.8
Gadd45g growth arrest and DNA-damage-inducible
45 gamma
8.4
Xrcc5 x-ray repair complementing defective repair in
Chinese hamster cells 5
11.8
Kit kit oncogene 13.0
Bcl6 B-cell leukemia/lymphoma 6 14.9
Cd74 CD74 antigen 17.5
Hbb-b1///b2 hemoglobin, beta adult major chain///minor chain 26.6
Hba-a1///a2 hemoglobin alpha, adult chain 1///hemoglobin
chain 2
30.6
Individual fold changes of genes differentially expressed in three
GATA2-ERT cell lines compared with the green florescent protein (GFP)
cell line. Differentially expressed genes involved in regulation of hemato-
poiesis (GO: 0030097) were shortlisted using DAVID bioinformatics
databases.
Table 1. Genes differentially expressed in GATA2-estrogen receptor
(ERT) vs. GFP cell line (cell proliferation)
Esr1 estrogen receptor 1 (alpha) 500.3
Mycn v-myc myelocytomatosis viral related oncogene,
neuroblastoma derived (avian)
59.7
Arrdc4 arrestin domain containing 4 20.2
Cd28 CD28 antigen 17.5
Il6st interleukin 6 signal transducer 16.0
S1pr1 sphingosine-1-phosphate receptor 1 14.9
Pawr PRKC, apoptosis, WT1, regulator 14.9
Fgf6 fibroblast growth factor 6 9.6
Trim24 tripartite motif-containing 24 9.2
Sox2 SRY-box containing gene 2 9.0
Tnfrsf9 tumor necrosis factor receptor superfamily,
member 9
20.2
Mab21l1 mab-21-like 1 (C. elegans) 21.1
Il2ra interleukin 2 receptor, alpha chain (probe 1) 22.1
Tnfsf10 tumor necrosis factor (ligand) superfamily,
member 10
26.0
Hes1 hairy and enhancer of split 1 (Drosophila) 28.5
Angptl2 angiopoietin-like 2 35.1
Fgf3 fibroblast growth factor 3 40.3
Arnt2 aryl hydrocarbon receptor nuclear translocator 2 45.3
Il2ra interleukin 2 receptor, alpha chain (probe 2) 104.0
Mab21l1 mab-21-like 1 (C. elegans) 165.0
Individual fold changes of genes differentially expressed in three
GATA2-ERT cell lines compared with the GFP cell line. Differentially
expressed genes involved in regulation of proliferation (GO: 0042127)
were shortlisted using DAVID bioinformatics databases.
Figure 4. Lymphoid block and myeloid expansion in recipients of
GATA2-ERT-transduced BM. Histogram depicting FACS analysis of
GFPþ cells in the B220þ, Thy 1.2þ, and Gr1þ populations of peripheral
blood from recipients 12 weeks posttransplant. Values are represented as
mean 6 SD. Total numbers of recipients in each group is as follows:
GFP group (n 5 2), GATA2-ERT group (n 5 6), GFP 1:4 group (n 5
7), and GATA2-ERT 1:4 group (n 5 10).
571S.K. Nandakumar et al./ Experimental Hematology 2015;43:565–577GATA2-ERT–transduced group retained high GFPþ fre-
quency in the Gr1þ myeloid population (82% 6 6), even
after fourfold dilution with mock cells. No transplanted an-
imals developed frank leukemia. Our results demonstrate
that GATA2-ERT causes myeloid bias and lymphoid block.
GATA2-ERT blocks lymphoid development after the
common lymphoid progenitor and expands granulocyte
monocyte progenitors
To define the differentiation stage at which GATA2-ERT
exerts its effects, we generated GATA2-ERT–transgenic
mice by lentiviral transduction of murine blastocysts. The
GATA2-ERT transgene was driven by the same MSCV pro-
moter as the retroviral vector used in previous transplant
experiments. Similar to the results of transplant, transgenic
mice consistently showed high GFP percentage in the Gr1þ
and Mac1þ populations and low GFP percentage in
the B220þ and CD3þ populations of peripheral blood
(Fig. 5A). Stem and progenitor cell compartments from
the GATA2-ERT–transgenic mouse BM were analyzed for
GFP expression. The LSK compartment had 35% GFPþ
cells, indicating that the GATA2-ERT transgene may have
been partially inactivated by position-effect variegation
during HSC specification (Fig. 5A). Alternatively,
GATA2-ERT expression can possibly affect HSC specifica-
tion in aorta gonads mesonephros or HSC expansion in fetal
liver, leading to a reduced level of GFPþ LKS cells. In the
myeloid lineage, there was a progressive increase in vector-expressing cells with differentiation. Granulocyte mono-
cyte progenitors (GMPs) showed higher GFP percentage
(72% 6 6) compared with common myeloid progenitors
(CMPs) (36% 6 4), suggesting that GATA2-ERT has a pro-
liferative effect on GMPs. A high frequency of GFPþ com-
mon lymphoid progenitors (CLPs; 70% 6 17) in the BM,
Figure 5. Maturation level of the GATA2-ERT-induced lymphoid block and myeloid expansion. (A) FACS analysis of GFPþ percentages of indicated
lymphoid and myeloid progenitors and mature cells from GATA2-ERT transgenic mouse BM and peripheral blood (n 5 3). CLP 5 Lineage, IL-7Raþ,
Sca1 low, c-Kitlo; CMP 5 Lineage, Sca1, c-Kitþ, FcgRmed, CD34med; GMP 5 Lineage, Sca1, c-Kitþ, FcgRhi, CD34hi. (B) FACS analysis of
GFPþ percentages of thymocytes from GATA2-ERT transgenic mice at indicated stages of differentiation (n 5 6). DN1 5 CD4, CD8, CD44þ,
CD25; DN2 5 CD4, CD8, CD44þ, CD25þ; DN3 5 CD4, CD8, CD44, CD25þ; DN4 5 CD4, CD8, CD44, CD25. (C) Quantitative real-
time PCR analysis of gene expression of endogenous (m) and total (m þ h) GATA2 in GFPþ and GFP LSK cells from GATA2-ERT transgenic mice
(n 5 3). Gene expression is first normalized to Gapdh and represented as a ratio compared with the GFP LSK. (D) GSEA analysis of gene expression
profile between GFP and GFPþ KSL cells from BM of GATA2-ERT transgenic mice (n 5 3). For each experiment, RNA was isolated from sorted
GFPþ or GFP KSL cells derived from pooled BM (seven GATA2-ERT transgenic mice per experiment). Enrichment plots shown for selected downregulated
gene sets identified by GSEA.
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partments of peripheral blood, suggested a CLP or post-
CLP block. To identify the block in T-cell development,
we examined the GFPþ frequency of thymocytes at
different stages of differentiation. We only detected GFPþ
thymocytes at the earliest double negative (DN) 1 stage
(19% 6 5), which was lower than the frequency of GFPþ
CLPs in the BM (Fig. 5B). These data suggest that T-cell
development is blocked at a prethymic stage, and the fewGATA2-ERT–expressing cells, which seed the thymus,
remain in the DN1 stage.
Although our data indicate that the lymphoid block is at
or after the CLP stage, it is possible that the lymphoid block
begins in the LSK compartment, where GATA2 is physio-
logically expressed. We also confirmed that there is a
2.7 times higher expression of GATA2 in GATA2-ERTþ
LSKs compared with GATA2-ERT LSKs (Fig. 5C). This
difference is entirely due to the GATA2-ERT transgene,
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GATA2 (Fig. 5C). To understand the molecular mechanism
behind GATA2-ERT–mediated lymphoid block, we per-
formed global gene expression profiling of GATA2-ERT–
expressing and–nonexpressing LSKs from transgenic
mice. Our analysis showed that 157 probe sets were upregu-
lated and 190 probe sets were downregulated in GATA2-
ERT–expressing LSKs. Furthermore, gene set enrichment
analysis (GSEA) showed downregulation of B-cell diffe-
rentiation, B-cell receptor signaling, IL7, and primary
immunodeficiency-related pathways (Fig. 5D). Crucial reg-
ulators of lymphoid fate (Vpreb1, Ebf1, Il7R, Rag1, Dntt,
Btla, Rag2, Lef1, and Tcf1) were significantly downregu-
lated in GATA2-ERT–expressing LSKs (Table 3).
DNA binding by GATA2-ERT is required for myeloid
expansion and lymphoid block
To determine whether GATA2-ERT might be functioning
by retaining other interacting proteins in the cytoplasm,Table 3. Changes in gene expression in GATA2-estrogen receptor (ERT)
expressing LSKs
Downregulation
Vpreb1 pre-B lymphocyte gene 1 13.74
Igll1 immunoglobulin lambda-like polypeptide 1 11.71
Ebf1 early B-cell factor 1 11.22
Blnk B-cell linker 8.47
Il7r interleukin 7 receptor 7.65
Rag1 recombination activating gene 1 7.63
Vpreb3 pre-B lymphocyte gene 3 5.62
Dntt deoxynucleotidyltransferase, terminal 5.18
Btla B and T lymphocyte associated 3.34
Rag2 recombination activating gene 2 3.22
Igh-6 immunoglobulin heavy chain 6 (heavy chain
of IgM)
3.09
Tcrg-V4 T-cell receptor gamma, variable 4 2.74
Lef1 lymphoid enhancer binding factor 1 2.71
Igj immunoglobulin joining chain 2.65
Tcrg-V2/Tcrg-V3 T-cell receptor gamma, variable 2/variable 3 2.39
Tcf7 transcription factor 7, T-cell specific 2.23
Upregulation
Vcam1 vascular cell adhesion molecule 1 28.75
C1qa complement component 1, q alpha polypeptide 20.52
C1qb complement component 1, q beta polypeptide 16.78
Mrc1 mannose receptor, C type 1 16.06
C1qc complement component 1, q C chain 10.63
Hba-a1///Hba-a2 hemoglobin alpha, adult chain 1/chain 2 6.21
Epx eosinophil peroxidase 5.34
Spic Spi-C transcription factor (Spi-1/PU.1 related) 5.21
Axl AXL receptor tyrosine kinase 5.00
Ear1/Ear12/
Ear2/Ear3
eosinophil-associated, ribonuclease A family,
member 1/12/2/3
4.89
Hmox1 heme oxygenase (decycling) 1 4.73
Igf1 insulin-like growth factor 1 3.55
Hbb-b1///Hbb-b2 hemoglobin, beta adult major chain/minor
chain
3.33
LSK 5 LinSca1þKitþ.
Individual fold changes of genes differentially expressed in GFPþ LSKs
compared with GFP LSKs (FDR ! 0.05 using local-pooled-error
(LPE) t test) of GATA2-ERT transgenic mice.such as IKAROS, EBF, E2A, and MEF2C, we generated
mutant forms of GATA2-ERT lacking the DNA-binding
domain and tested them in functional assays. Two point
mutations, C352P and C370P, were made in the second
zinc finger of GATA2, which is critical for DNA binding,
based on previous studies (Supplementary Figures E1A
and E1C, online only, available at www.exphem.org)
[24–26]. C352P and C370P mutant proteins were expressed
at similar levels to the wild-type GATA2-ERT in transduced
BM cells (Supplementary Figure E8A, online only, avail-
able at www.exphem.org). Both mutants also displayed
low-level nuclear localization in the absence of TAM,
similar to wild-type GATA2-ERT (Supplementary
Figure E8B, online only, available at www.exphem.org).
We confirmed that C352P and C370P mutants showed a
loss of DNA binding to the consensus WGATAR motif
by electrophoretic mobility shift assay (Fig. 6A). In vitro,
lack of DNA binding abolished the growth advantage of
GATA2-ERT–transduced BM cells over mock cells in
liquid culture (Fig. 6B). C352P and C370P mutations also
abolished the self-renewal capacity of GATA2-ERT in
serial CFU-C assays. Cells harvested from primary colonies
of GATA2-ERT wild-type groups formed at least sevenfold
higher secondary colonies than either mutant or the control
GFP groups (Fig. 6C). These results indicate that the
competitive advantage and increased self-renewal conferred
by GATA2-ERT require its DNA-binding activity.
Finally, to determine whether DNA-binding is required
for myeloid expansion and lymphoid block in vivo, trans-
plant experiments were performed as described above
with the C352P mutant. At 12 weeks posttransplant, undi-
luted GATA2-ERT recipients showed low GFPþ frequency
of B220þ cells (25%) and CD3þ cells (50%) as well as high
frequency in Gr1þMac1þ cells (94%) when compared with
the control undiluted GFP recipients, which displayed uni-
form GFP positivity in all three subsets (B220þ, 76%;
CD3þ, 73%; Gr1þMac1þ, 84%; Fig. 6D). The undiluted
C352P mutant group showed higher GFPþ frequency of
B220þ cells (50%) and CD3þ cells (46%), similar to the
Gr1þMac1þ cells (75%), more closely resembling the
GFP groups (Fig. 6D). The GFP mean fluorescence inten-
sity (MFI) in B220þ cells and Thy1.2þ cells of GATA2-
ERT recipients was much lower than in myeloid cells,
indicating that cells that escape lymphoid block have rela-
tively low GATA2-ERT expression (Fig. 6E and 6F). The
C352P recipients showed similar GFP MFI between the
myeloid and lymphoid subsets, which demonstrates that
dose-dependent lymphoid block requires DNA-binding
activity (Fig. 6E and 6F). However, since the GFP percent-
age and MFI of CD3þ cells were similar between the
GATA2-ERT and C352P groups, it is still possible that
the T-cell block is mediated by protein-protein interactions
in the cytoplasm. Upon fourfold dilution with mock cells,
only the GATA2-ERT wild-type maintained a high GFP
percentage in Gr1þMac1þ cells (62%) compared with
Figure 6. DNA-binding activity of GATA2-ERT is required for myeloid expansion and lymphoid block. (A) Electrophoretic mobility shift assay of wild-type
and mutant GATA2-ERT and wild-type GATA2. GATA2 and GATA2-ERT proteins synthesized in vitro were bound to P32-labeled mouse a-globin promoter
oligonucleotide (containing a GATA binding site) in the absence or presence of 500fold unlabeled oligonucleotides, labeled ‘‘D.’’ Position of free probe is
labeled ‘‘1,’’ protein/DNA complexes containing GATA2 are labeled ‘‘2,’’ and GATA2-ERT labeled ‘‘3.’’ (B) FACS Analysis of GFPþ percentages of trans-
duced primitive BM cells (after 5-fluorouracil treatment) at different time points in liquid culture (n 5 3). Transduced cells were diluted at day 0 with mock-
transduced cells to start at a uniform GFP percentage (25% to 28%) in all samples. (C) Total CFU-Cs from primary and secondary colony plating of
transduced, lineage-depleted BM cells. Cells were plated at 1.25  103 per plate in the primary plating followed by 2.5  104 per plate for secondary plating.
(D) FACS analysis of percentage of GFPþ cells in the B220þ, CD3þ, and Gr1þMac1þ populations in peripheral blood of recipients at 12 weeks posttrans-
plant. Values are represented as mean 6 SD of 10 recipients in each group. (E) Comparison of GFP expression between B220þ cells, CD3þ cells, and
Gr1þMac1þ cells in representative GFP, GATA2-ERT, and C352P transplant recipients at 16 weeks posttransplant. (F) GFP MFI ratios in myeloid cells
against B220þ and CD3þ cells in GFP, GATA2-ERT, and C352P transplant recipients at 16 weeks posttransplant (n 5 10).
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demonstrate that the DNA-binding activity of the GATA2-
ERT is also required for myeloid expansion in vivo.Discussion
In this work, we demonstrate for the first time, to our
knowledge, that low-level nuclear GATA2 promotes
myeloid self-renewal and a lymphoid differentiation block,
which are potentially critical preleukemic events. Both
overexpression [8,9] and gain of function mutations of
GATA2 [11] as well as loss of function mutations of
GATA2 [27–32] have been reported in acute myeloid leuke-
mia. Whether GATA2 overexpression contributes function-
ally to transformation has been confusing, because previous
studies, in which there was high-level enforced expression
by retroviral insertion of a GATA2 transgene, led to loss
of in vitro colony-forming potential and a loss of HSC
reconstitution potential [12,13], outcomes that conflict
with the idea that GATA2 might drive the cellular prolifer-
ation. Here, we made use of the leaky nuclear localization
of a conditional TAM-inducible GATA2-ERT protein to
obtain lower nuclear GATA2 levels that are more physio-
logically comparable to those observed in leukemic blasts.
At these lower levels, we observe increased proliferative
capacity of myeloid progenitors and block in lymphoid dif-
ferentiation but not leukemia.
We confirmed by confocal imaging and subcellular frac-
tionation that GATA2-ERT protein translocates to the
nucleus of BM cells and myeloid cell lines in the absence
of TAM. The nuclear concentration in the absence of
TAM is twofold lower than that observed in the presence
of TAM. Lower nuclear GATA2 concentration was critical
for high proliferation and self-renewal capacity of myeloid
progenitors, because at higher nuclear GATA2 concentra-
tion directed by 100 nmol/L TAM, we observe cell cycle
arrest and loss of colony-forming ability, consistent with
previously published reports [33,34]. Protein interactions
by cytoplasmic GATA2-ERT do not explain these effects,
because the DNA-binding activity is required for prolifera-
tion of myeloid progenitors in vivo and in vitro.
We observe a myeloid expansion and lymphoid block in
both GATA2-ERT transplant and transgenic mice. Detailed
analysis of the BM stem and progenitor compartments of
GATA2-ERT transgenic mice revealed myeloid expansion
beginning at the GMP stage. The GMP compartment has
previously been shown to depend on GATA2 dose, and
GMP numbers are reduced in GATA2þ/ mice [35]. A
lymphoid block is observed in both T and B lineages.
This block starts at or after the CLP stage in transgenic
animals, but gene expression analysis on GATA2-ERT–
expressing multipotent progenitors (MPPs) showed a down-
regulation of lymphoid-priming markers such as IL7R; the
transcription factors Ebf1, Lef1, and Tcf7; and effectors
Rag1, Rag2, Dntt, Btla, Vpreb1, Igh-6, and Tcrg. There isconsiderable overlap of downregulated genes between
GATA2-ERT–expressing MPPs, Mef2c/ MPPs, and
Tcfe2/ MPPs [36,37]. GATA2 might antagonize the ac-
tivity of transcription factors E2A and Mef2c to prevent
lymphoid priming in the MPPs.
Requirement for high expression of Nmyc and HoxA9 in
the GATA2-ERT cell lines suggest that Nmyc and HoxA9
are potential GATA2 targets, mediating proliferative behav-
iors in myeloid progenitors. Enforced expression of Nmyc
increases the proliferation and self-renewal of myeloid pro-
genitors [21]. Nmyc is also one of the top five differentially
regulated genes between GATA2 high- and intermediate-
expressing HSCs [6]. Overexpression of HoxA9 in BM cells
expands myeloid cells with a block in lymphoid develop-
ment at the Pre-B cell stage [23]. Overexpression of
HoxA9 also immortalized BM cells into granulocyte-
macrophage colony–stimulating factor–dependent promye-
locyte cell lines [38]. Recently, GATA2-HOXA9 fusion has
also been reported in pediatric acute megakaryoblastic leu-
kemia [39].
GATA2-ERT generated IL-3-dependent myeloid cell
lines at a higher frequency than controls, and continued
expression of GATA2-ERT was required for proliferation
of these cell lines. Expression of many leukemic gene
fusions, such as MLL-ENL, MLL-AF9, MOZ-TIF2,
and NUP98-HOXA9, can cause increased self-renewal of
myeloid progenitors, immortalization of primary BM cells
in vitro, and leukemia upon transplantation [22,40–43].
Nevertheless, we did not observe leukemia in both
GATA2-ERT transplant and transgenic mice, indicating
that additional cooperating mutations are required for frank
transformation. Our results demonstrate that GATA2 con-
tributes to proliferative behaviors and lineage commitment,
revealing the importance of precise control of GATA2
dosage in regulating these activities.Acknowledgments
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Supplementary methods
Lentiviral shRNA vector design, cloning of hairpins, and
vector production
Murine Stem Cell Virus (MSCV) mir30 phosphoglycerate
kinase (PGK) puro internal ribosomal entry site [IRES]
Red Fluorescence Protein (RFP) (‘‘LMP RFP vector’’), a
retroviral mir30-based short hairpin RNA (shRNA) vector,
was a gift from Dr. Richard Gilberson’s laboratory. The
LMP RFP vector is a derivative of the LMP vector from
Gregory Hannon’s lab [44]. The PGK puro IRES fragment
was replaced with the PGK fragment from the pCL-c-
MNDU3 PGK green florescent protein (GFP) vector using
the BlpI and NcoI restriction sites. The RFP reporter was
replaced with polymerase chain reaction (PCR)-amplified
mCherry cDNA. The entire mir30 cassette with mCherry
reporter was moved to the lentiviral backbone of
pCL20cGFP vector using ClaI and EagI sites [45]. Finally,
an XhoI site outside the viral LTR was removed to generate
the pCL20c-mir30mcherry vector. This vector was used for
direct, single-step cloning of the hairpins.
137bp oligonucleotides encoding various shRNA-mir
folds were generated using RNAi Central (http://cancan.
cshl.edu/RNAi_central). We designed three to five oligonu-
cleotides for each of the gene targets and performed single-
strand template PCR as previously described [46]. The PCR
products were digested using EcoRI and XhoI sites and
ligated into the unique XhoI and EcoRI sites in the
pCL20c-mir30mcherry vector. Vesicular stomatitis virus
G protein (VSV-G)-pseudotyped lentiviral vector particles
were prepared using a four-plasmid system with transient
transfection of 293T cells as previously described [47].
Immunostaining and confocal microscopy
Cells were incubated on retronectin-coated coverslips (22 X
22-1; Fisherbrand, Pittsburgh, PA) at 37C for 40 min. Af-
ter cell attachment, the coverslips were fixed with 4% para-
formaldehyde (30 min), permeablized with 0.1% Triton X-
100 (15 min), and blocked with Fx-signal enhancer (Invi-
trogen, Carlsbad, CA) for 30 min. Primary antibody was
incubated overnight at 4C and secondary antibody for
1 hour at room temperature, followed by 4,6-diamino-2-
phenylindole (DAPI; 0.2 mg/mL) for 10 min, with three
washes with phosphate-buffered saline (PBS) in between.
After a final wash with water, the coverslips were mounted
on glass slides (Fisherbrand, Pittsburgh, PA) using Prolong
Gold with DAPI-mounting media (Invitrogen, Carlsbad,
CA) and visualized in Zeiss LSM 510 NLO Meta confocal
microscope (Carl Zeiss, Peabody, MA).
Cell cycle assays
GATA2-ERT cell lines cultured with 100 nmol/L Tamox-
ifen (TAM) or ethanol were lysed with propidium iodide
(PI) for DNA content analysis at the time points indicated.
We performed cell cycle analysis on the shRNA vector-
transduced GATA2-ERT cell lines by incubating with
Hoechst 33342 at 10 mg/mL for 1 hour, followed by
FACS analysis. ModFit Analysis (Verity Software House,
Topsham, ME) was performed on total population (PI
method) or select gated population (Hoechst method).
RNA isolation and real-time polymerase chain reaction
RNAwas isolated with RNAqueous-Micro Kit or Ribopure
Kit (Life Technologies, Carlsbad, CA) and cDNA synthe-
sized with Superscript VILO (Life Technologies, Carlsbad,
CA). Real-time PCR was performed using TaqMan Fast
Universal PCR Master Mix, No AmpErase UNG in the
Step One Plus Real-Time PCR System (Life Technologies,
Carlsbad, CA).
Flow cytometry and cell sorting
Single-cell suspensions were prepared from thymus and
bone marrow (femoral and tibial bones) by passage
through a 70-micron cell strainer (BD, San Jose, CA).
Cells were resuspended in PBS with 2% fetal bovine
serum. About 70 mL of blood was obtained from mice
via the retro-orbital vein puncture, and red blood cell lysis
was performed with BD FACS Lyse Wash Assistant. Cells
were stained for 30 min with fluorochrome-conjugated or
biotin-conjugated antibodies. Cells were then washed
with excess medium and were resuspended in PBS with
2% fetal bovine serum containing a dead cell marker
(PI or DAPI). FACSCalibur, LSR, and LSRII (BD Biosci-
ences, San Jose, CA), were used for flow cytometry, and
BD Aria (BD Biosciences, San Jose, CA) was used for
cell sorting. For sorting LSK cells, BM from transgenic
mice was enriched for Sca1 and c-kit markers using
anti-PE and anti-allophycocyanine (APC) magnetic beads
in AutoMACS before staining with Lineage–phycoery-
thrin (PE)–cyanin (Cy) 7 antibodies. For sorting individ-
ual progenitor and stem cell populations, BM from
C57Bl/6 mice were lineage depleted, as described above,
before being stained with other progenitor and stem cell
markers.
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Supplementary Table E2. Antibodies used for immunostaining and Western blot
Name Dilution Company Catalogue number
aGATA2 1:1,000 (WB), 1:50 (IHC) Santa Cruz, Dallas, TX sc-9008
aER alpha 1:1,000 (WB), 1:100 (IHC) Santa Cruz, Dallas, TX sc-542
aBcl11a 1:200 (WB) Abcam, Cambridge, MA ab19487
aLamin B 1:200 (WB) Santa Cruz, Dallas, TX sc-6216
aGAPDH 1:25,000 (WB) Millipore, Billerica, MA MAB374
aGFP 1:1,000 (WB) Cell Signaling, Danvers, MA #2555
Goat antirabbit HRP 1:10,000 (WB) Santa Cruz, Dallas, TX sc-2004
Goat antimouse HRP 1:10,000 (WB) Jackson ImmunoResearch, Bar Harbor, ME 115-035-062
Rabbit anti-goat HRP Fc Fragment specific 1:10,000 (WB) Jackson ImmunoResearch, Bar Harbor, ME 305-036-008
Goat antirabbit Alexa Flour 555 1:100 (IHC) Invitrogen, Carlsbad, CA A21429
Donkey antirabbit Texas Red 1:50 (IHC) Jackson ImmunoResearch, Bar Harbor, ME 711-075-152
IHC 5 Immunostaining; WB 5 Western blot.
Supplementary Table E1. TaqMan primer probe sets obtained from
Applied Biosystems (Waltham, MA) for real-time PCR
Gene name Catalogue number
mouse þ human GATA2 Mm00492302_g1
mouse GATA2 Mm00492300_m1
mouse mycN Mm00627179_m1
mouse hoxA9 Mm00439364_m1
mouse GAPDH Mm9999915_g1
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Supplementary Table E3. Antibodies used for flow cytometry and cell sorting
Epitope Clone Conjugate Company
CD3e 145-2C11 APC BD, San Jose, CA
CD3c 17-A2 PE BD, San Jose, CA
B220 RA3-6B2 eFlour605, PEcy7 BD, San Jose, CA
Mac1 M1/70 APC-Cy7, Alexa-700, PE-Cy7 BD, San Jose, CA
Gr-1 RB6-8C5 APC, APC-Cy7, PE-Cy7 BD, San Jose, CA
CD34 RAM34 PE BD, San Jose, CA
FcgR 2.4G2 Alexa-700 BD, San Jose, CA
Sca1 E13-161.7 PE, Biotin BD, San Jose, CA
c-kit 2B8 APC, APC-Cy7 BD, San Jose, CA
CD127 A7R34 APC BD, San Jose, CA
Streptavidin PE Texas Red, PE-Cy7 BD, San Jose, CA
CD44 1M7 PE-Cy7 BD, San Jose, CA
CD25 PC61 APC BD, San Jose, CA
CD4 L3T4 APC-Cy7, PE-Cy7 BD, San Jose, CA
CD8a 53-6.7 Alexa700, PE-Cy7 BD, San Jose, CA
Ter119 TER119 PE-Cy7 BD, San Jose, CA
FcεR1 MAR-1 Biotin Ebioscience, San Diego, CA
Supplementary Table E4. Targeting sequence of the mir30-based shRNAs used in the study
Vector Gene target Target 22mer
NS Non-silencing - CTCTCGCTTGGGCGAGAGTAAG
shGFP GFP CDS GGCACAAGCTGGAGTACAACTA
shGATA2_122 Human GATA2 CDS TCCAGACGAGGTGGACGTCTTC
shGATA2_644 Human GATA2 CDS GTCACTGACGGAGAGCATGAAG
shGATA2_991 Human GATA2 CDS CACTCATCAAGCCCAAGCGAAG
shGATA2_1250 Human GATA2 CDS GTCAAAGTGCATGCAGGAGAAG
shNmyc_2 Mouse Nmyc CDS GCCTGGCGAGCTGATCCTCAAG
shNmyc_3 Mouse Nmyc 30UTR AACAAACATTGTGTTGACATTA
shNmyc_5 Mouse Nmyc 30UTR TTTACTGTATTTGTTCATGTTT
shHoxa9_5 Mouse HoxA9 CDS AGGTCAAGATCTGGTTCCAGAA
shHoxa9_6 Mouse HoxA9 CDS CTGACTGACTATGCTTGTGGTT
shHoxa9_7 Mouse HoxA9 CDS AGGAGTTTCTGTTTAACATGTA
shBcl11a Mouse Bcl11a CDS AATCCATGAGTGTTCTGTGCGG
CDS 5 Coding DNA sequence; UTR 5 untranslated region.
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Supplementary Figure E1. Retroviral vectors used in this study. (A) Schematic of the MSCV-based retroviral vectors used in the study. The vectors contain
an IRES that allows cap-independent translation of the green florescent protein (GFP) coding sequence. Thus, transgene GATA2-ERT dose in individual cells
can be predicted based on GFP expression (MFI). (B) The amino acid sequences of the linker region connecting human GATA2 and the ERT in the MSCV
GATA2-ERT vector are also shown. (C) Amino acid sequences of the C-terminus zinc finger with the locations of the point mutations. The four cysteine
residues coordinating the zinc ion of the second finger are marked in green. CF 5 C-terminus zinc finger; NF 5 N-terminus zinc finger.
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Supplementary Figure E2. Growth effects of the absence and presence
of TAM on GATA2-ERT cell lines. (A) Growth curves of GATA2-ERT
and GFP cell lines treated with 100 nmol/L TAM or an equivalent volume
of ethanol. (B) Cell cycle analysis of GATA2-ERT and GFP cell lines
treated with 100 nmol/L TAM or ethanol. At 24 and 48 hours posttreat-
ment, cells are lysed with PI and analyzed by flow cytometry. Results
are shown as mean 6 SD of experiments on three different GATA2-ERT
cell lines and one GFP cell line. EtOH 5 Ethanol.
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Supplementary Figure E3. Subcellular localization of GATA2-ERT in GATA2-ERT cell lines and GPE-86 producer cells. (A) GATA2-ERT and GFP cell
lines were attached to retronectin-coated coverslips in the presence of 100 nmol/L TAM or EtOH for 12 hours, then fixed and stained (1-aGATA2, 2-a-
rabbit Alexa Flour 555). Imaging was performed using Zeiss LSM 510 Meta point scanning confocal microscope with a Plan Apochromat 63X/1.4 Oil objec-
tive and zoom scan of 1.3. (B) GPE-86 GFP and GATA2-ERT cells were attached to Poly-D lysine-coated, glass-bottom dishes overnight and then treated
with 100 nmol/L TAM/ethanol for 24 hours before fix and stain (1-aGATA2, 2-a-rabbit Texas Red). Imaging was performed using a Nikon C1Si laser
scanning confocal microscope (Nikon, Tokyo, Japan) with a Plan Apochromat 60.0X/1.45/.13 Oil objective. Red represents GATA2-ERT, and blue represents
DAPI. Top row shows GATA2-ERT staining, and bottom row shows an overlay with DAPI. EtOH 5 Ethanol.
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Supplementary Figure E4. Expression levels of transgene GATA2-ERT
and endogenous GATA2 in primary BM cells posttransduction. Proteins
from lineage-depleted BM cells transduced with GATA2-ERT or GFP vec-
tors were subfractionated into cytoplasmic and nuclear fractions and West-
ern blotted for GATA2-ERT, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; cyto), and Lamin B (Nuc). Total fraction (Total) was prepared
by boiling lysis in Laemelli buffer. GATA2-ERT protein was detected us-
ing a polyclonal anti-GATA2 antibody (H-116), which can detect both
endogenous GATA2 (50kd) and GATA2-ERT (83kd). Nuclear fraction
from primary BM cells transduced with GATA2 vector is shown as a pos-
itive control for GATA2. Cyto 5 Cytoplasmic; nuc 5 nuclear.
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Supplementary Figure E5. Knockdown of GATA2-ERT inhibits proliferation of the immortalized cell lines due to cell cycle arrest and differentiation. (A)
Schematic of the mir30-based lentiviral shRNAvector used in the study. (B) GATA2-ERT cell line was transduced with shRNAvectors targeting green flores-
cent protein (GFP) (shGFP), human GATA2 (shGATA2), and a scrambled sequence (NS). Three days posttransduction, mCherryþ cells were sorted and lysed
for protein and Western blotted against GATA2-ERT (a-ER alpha) and GAPDH. Untransduced GATA2-ERT and GFP cell lines were loaded as controls in the
first two lanes. (C) GATA2-ERT knockdown inhibits proliferation of GATA2-ERT immortalized cell lines. Percentages of mCherryþ cells in GATA2-ERT
(n5 3) and GFP (n5 1) cell lines transduced with shGFP and NS vectors at different time points in liquid culture. Values are represented as mean6 SD. (D)
Cell cycle analysis using Hoechst was performed at day 2 and day 7 using GATA2-ERT cell lines from above (n5 3). Cell cycle effects on GATA2-ERT cells
transduced with shGFP were compared with NS-transduced cells. (E) FACS analysis of percentages of Grþ cells at 3 days and 6 days posttransduction with
NS and shGFP vectors. Only the transduced mCherryþ cells were gated for analysis.
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Supplementary Figure E6. Knockdown efficiency of the Nmyc- and
HoxA9-targeting vectors in GATA2-ERT cell line. (A, B) GATA2-ERT
cell line was transduced with shRNA vectors targeting Nmyc (shNmyc),
HoxA9 (shHoxA9), and a scrambled sequence (NS). Three days posttrans-
duction, mCherryþ cells were sorted for total RNA extraction followed by
quantitative real-time PCR. Expression levels of Nmyc and HoxA9 after
knockdown relative to the scrambled vector are shown. GAPDH was
used as the endogenous control.
Supplementary Figure E7. Knockdown of Bcl11a does not recapitulate
GATA2-ERT loss in immortalized cell lines. (A) Murine erythroleukemia
(MEL) cells cells were transduced with shRNA vectors targeting Bcl11a
(shBcl11a) and a scrambled sequence (NS). Three days posttransduction,
cells were lysed for protein and Western blotted against Bcl11a and Actin.
(B) FACS analysis of mCherry percentages of GATA2-ERT cell lines
transduced with the shRNA vectors targeting Bcl11a, GATA2-ERT, and
scrambled sequence at different time points in liquid culture.
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Supplementary Figure E8. Expression and subcellular localization of GATA2-ERT mutants in primary BM cells. Lin BM cells were transduced with the
wild-type and mutant GATA2-ERT vectors and control GFP vector at similar MOI. (A) At 3 days posttransduction, proteins were isolated and Western blotted
for GATA2-ERT (a ER alpha) and GAPDH. All the groups had similar GFP percentages (60%–70%). (B) Immunostaining was also performed at the same
time point posttransduction. Cells were attached to retronectin-coated coverslips for 40 min before fix and stain. Green represents Green Fluorescence Protein
(GFP), red represents GATA2-ERT (1-aER alpha, 2-a-rabbit Alexa Flour 555), and blue represents DAPI. Imaging was performed using Zeiss LSM 510
Meta point scanning confocal microscope with a Plan Apochromat 63X/1.4 Oil objective and zoom scan of 3.0.
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